复方苦参注射液辅助治疗非小细胞肺癌的Meta分析

目的:系统评价复方苦参注射液辅助治疗非小细胞肺癌(NSCLC)的疗效和安全性。方法:计算机检索PubMed、EMbase、Cochrane图书馆、中国生物医学文献数据库(CBM)、中文科技期刊全文数据库(VIP)、万方数字化期刊全文库、中国期刊全文数据库(CNKI),全面收集在常规含铂与第3代化疗药物二联应用的基础上加用复方苦参注射液辅助治疗NSCLC的随机对照试验(RCT),进行质量评价和Meta分析。结果:共纳入16项RCT,合计1297例患者。Meta分析结果显示,与对照组比较,复方苦参注射液与NP(长春瑞滨+铂类)、TP(紫杉醇+铂类)方案联用的总有效率[RR=1.35,95%C(I1.09,1.69);RR=1.25,95%C(I1.02,1.53)]、生存质量改善率[RR=1.67,95%CI(1.35,2.07);RR=1.98,95%CI(1.51,2.59)]、中重度白细胞减少[RR=0.49,95%CI(0.35,0.69);RR=0.57,95%CI(0.37,0.88)]、中重度胃肠道反应[RR=0.58,95%C(I0.41,0.83);RR=0.45,95%C(I0.30,0.68)]等差异都具有统计学意义。复方苦参注射液与GP(吉西他滨+铂类)方案联用也有上述趋势。结论:基于当前证据,复方苦参注射液联合NP、TP方案能提高近期疗效、降低毒副作用,但远期疗效有待进一步证实。

A Meta-analysis of Compound Sophora flavescens Injection for the Treatment of Non-Small Cell Lung Cancer

OBJECTIVE： To review the effect and safety of compound Sophora flavescens injection for the treatment of non-small cell lung cancer（NSCLC）. METHODS： We set include and exclude criterion, and searching strategy, databases of PubMed, EMBase, Cochrane, CBM, VIP, Wanfang, CNKI were searched, randomized trials （RCT） of compound S. flavescens combined with the third generation chemotherapy drugs and platinum for the treatment of NSCLC were gathered. Quality was evalu- ated and meta-analysis was carried out. RESULTS ： 16 RCT were included. Meta-analysis indicated that the differences of total ef- fect rate[RR= 1.35,95 % CI （ 1.09, 1.69） ; RR---- 1.25,95 % CI （ 1.02, 1.53 ）], life of quality improvement rate[RR= 1.67,95 % CI （ 1.35, 2.07） ;RR----1.98,95%CI（1.51,2.59）], leucopenia （Ⅲ-Ⅳ）[RR=0.49,95%CI（0.35,0.69）;RR=0.57,95%CI（0.37,0.88）], gastro intestinal reaction （ Ⅲ-Ⅳ ） [RR=-.58,95%CI（0.41,0.83） ;RR=0.45,95%CI（0.30,0.68）] and baldness in NP and TP group com- bined with compound S. flavescens were significant. And compound S. flavescens combined with GP trended to be the same effect above. CONCLUSION： Based on current evidence, compound S. flavescens combined with NP, TP could improve short term effectiveness and decrease toxic and side-effects; long term effectiveness is hoped.